New guidelines recommend a sequential treatment approach for episodic migraine, starting with beta-blockers, antiseizure medications, SNRIs, and TCAs. CGRP antagonists and monoclonal antibodies are ...

BARCELONA — Restarting an anti-CGRP monoclonal antibody (mAb) for migraine prevention after a gap in treatment often leads to a lower efficacy rate in the second treatment period, a new study suggests ...

Please provide your email address to receive an email when new articles are posted on . Rimegepant offered superior sustained pain relief, pain freedom and normal function up to 48 hours. Most adverse ...

CGRP may cause inflammation and pain in the nervous system of people who have migraine episodes. CGRP also causes blood vessels in the head to widen, which experts think may lead to migraine symptoms.

The past several years have seen more advancements in migraine-specific treatments than in the past three decades. Let that sink in. Since 2018, several new therapies have emerged to both treat ...

According to current data, migraines are one of the most common neurological disorders worldwide and in the United States. Worldwide, migraines affect about 40% of the population (3.1 billion people).